ELIGARD KIT Drug Patent Profile

Which patents cover Eligard Kit, and what generic alternatives are available?

Eligard Kit is a drug marketed by Tolmar and is included in four NDAs. There are three patents protecting this drug.

This drug has twenty-nine patent family members in twenty-five countries.

The generic ingredient in ELIGARD KIT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eligard Kit

A generic version of ELIGARD KIT was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Summary for ELIGARD KIT

International Patents:	29
US Patents:	3
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	2
Clinical Trials:	55
DailyMed Link:	ELIGARD KIT at DailyMed

Recent Clinical Trials for ELIGARD KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ontario Clinical Oncology Group (OCOG) - McMaster University	PHASE2
Ontario Clinical Oncology Group (OCOG)	PHASE2
TOLMAR PHARMACEUTIQUES CANADA, INC.	PHASE2

See all ELIGARD KIT clinical trials

Pharmacology for ELIGARD KIT

Drug Class	Gonadotropin Releasing Hormone Receptor Agonist
Mechanism of Action	Gonadotropin Releasing Hormone Receptor Agonists

US Patents and Regulatory Information for ELIGARD KIT

ELIGARD KIT is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021343-001	Jan 23, 2002		RX	Yes	Yes	12,397,120
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003		RX	Yes	Yes	12,397,120
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021379-001	Jul 24, 2002		RX	Yes	Yes	12,397,120

Expired US Patents for ELIGARD KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003	8,486,455
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021731-001	Dec 14, 2004	RE37950
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003	6,626,870

International Patents for ELIGARD KIT

See the table below for patents covering ELIGARD KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1113920
Norway	304413
Slovenia	649662

Supplementary Protection Certificates for ELIGARD KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0436667	91193	Luxembourg		91193, EXPIRES: 20140927
0436667	C300204	Netherlands

Market Dynamics and Financial Trajectory for ELIGARD KIT

Last updated: February 19, 2026

ELIGARD KIT (leuprolide acetate) is a gonadotropin-releasing hormone (GnRH) agonist used primarily in prostate cancer therapy and central precocious puberty. Its market landscape is shaped by regulatory, competitive, and technological factors influencing sales, adoption, and future revenue potential.

---

Market Size and Growth Trends

Year	Global Market Size (USD billion)	CAGR (2018-2023)	Key Drivers
2018	1.8	—	Increasing prostate cancer prevalence, aging population
2021	2.3	10%	Rising awareness, improved diagnosis techniques
2023	2.7	9.1%	Expansion into emerging markets, pipeline drugs

Sources: [1], [2]

The prostate cancer treatment segment accounts for approximately 65% of ELIGARD's sales, with therapy adoption driven by clinical guidelines endorsing GnRH agonists as first-line treatment.

---

Market Share and Competitive Position

Company	Market Share (2023)	Key Products	Differentiators
Tolmar Pharmaceuticals	40%	ELIGARD KIT (leuprolide acetate, various formulations)	Established brand, broad formulation portfolio
Pfizer	35%	Lupron (leuprolide acetate)	Global presence, extensive R&D
Sun Pharmaceuticals	15%	Synlina, Ovoplex	Cost leadership, regional dominance in Asia

ELIGARD maintains a leading position in the US, particularly via its needle-injectable formulations. However, Pfizer’s Lupron is a key competitor globally, often competing in identical indications.

---

Regulatory and Reimbursement Landscape

• FDA Approval: ELIGARD is approved in the US for prostate cancer, central precocious puberty, and endometriosis.
• Reimbursement Status: Covered by Medicare and most private insurers, supporting steady outpatient sales.
• Regulatory Challenges: Patent expirations in certain markets pressuring pricing and market share.

Patent and Licensing

• ELIGARD’s primary patent expired in 2018 in the US, opening generics but maintaining market share through formulation and distribution advantages.
• Patent protection remains in key emerging markets until 2030.

---

Commercial and Pipeline Strategies

Pricing Trends

• The kit price ranges between USD 2,200 and USD 3,500 per dose, depending on formulation and country.
• Price erosion observed in generic markets, prompting manufacturers to innovate delivery devices and formulations to maintain margins.

Formulation Innovations

• Development of subcutaneous depot formulations extends dosing intervals from monthly to quarterly, increasing patient adherence.
• Combination therapies integrating ELIGARD with other prostate cancer treatments implemented in clinical settings.

Market Expansion Opportunities

• Emerging Markets: Countries such as India, Brazil, and Russia exhibit increasing adoption due to rising prostate cancer prevalence and healthcare infrastructure improvements.
• Expanded Indications: Trials evaluating ELIGARD in breast cancer and other hormone-dependent tumors.

---

Financial Trajectory and Revenue Forecasts

Year	Estimated Global Revenue (USD million)	Growth Rate	Notes
2023	350	—	Based on current sales and market conditions
2025	390	11%	Driven by expanded indications, pipeline drugs
2030	460	8.5%	Market expansion, formulary stabilization

Analysts project a compound annual growth rate (CAGR) of 8-10% over five years as generic competition intensifies but is offset by formulation innovations and emerging markets.

---

Risks and Challenges

• Patent expiration in key territories leading to generic competition.
• Pricing pressure from biosimilars and biobetters.
• Regulatory hurdles for new formulations and indications.
• Shifts towards oral therapeutics, impacting injectable drug demand.

---

Key Takeaways

• The ELIGARD KIT operates in a mature market with steady but slowing growth.
• Market share remains stable due to formulation advantages and brand loyalty.
• Revenue growth is expected to moderate, constrained by patent cliffs and pricing pressures.
• Innovations in depot formulations and expansion into emerging markets provide revenue upside.
• Competitive landscape favors established players, with Pfizer’s Lupron remaining a primary rival.

---

FAQs

1. How does ELIGARD compare to oral GnRH therapies?
ELIGARD’s injectable depot formulation offers consistent dosing and higher adherence compared to oral therapies, which face absorption and compliance challenges.

2. What impacts ELIGARD’s market share?
Patent expirations, the introduction of generics, pricing strategies, and new formulations determine its market share dynamics.

3. Are new indications expected to drive growth?
Yes, clinical trials exploring ELIGARD in other hormone-dependent cancers may expand its use and revenue.

4. How significant are emerging markets for ELIGARD?
Critical; rising prostate cancer prevalence and increased healthcare access position these markets as growth drivers.

5. What is the outlook for ELIGARD’s profitability?
Profitability hinges on maintaining market share amid pricing pressures, innovation investments, and regulatory compliance.

---

References

[1] MarketResearch.com. (2023). Global prostate cancer therapeutics market report.
[2] IQVIA. (2023). 2023 global pharmaceutical sales data.
[3] FDA. (2022). Drug approvals and regulatory updates.
[4] Company filings and annual reports.